Nearly two years after approving the nation’s first biosimilar, the FDA released its draft guidance recommending how sponsors of proposed therapeutic proteins can demonstrate interchangeability with reference products when applying for marketing approval.
The interchangeability designation demands a greater burden of proof than for the approval of biosimilars. The most important difference requires that sponsors of proposed interchangeable products conduct one or more switching studies